Research programme: anticancer therapies - Moleculin Biotech/University of Texas M. D. Anderson Cancer Center

Drug Profile

Research programme: anticancer therapies - Moleculin Biotech/University of Texas M. D. Anderson Cancer Center

Alternative Names: 2-DG prodrug; CP2005; Degrasyns; Tyrphostins; WP 1122; WP1066; WP1106; WP1129; WP1130

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Moleculin
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Janus kinase-2 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Oct 2016 Pharmacodynamics data from a preclinical study in Cancer released by Moleculin Biotech
  • 26 Oct 2016 Moleculin Biotech plans a clinical trial of WP 1122 for Cancer
  • 09 Aug 2016 M.D. Anderson Cancer Center extends the license agreements and expands sponsored research agreement with Moleculin Biotech for WP1066 for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top